3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Brain Neoplasms
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Neoplasm Metastasis
2
Glioma
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Solid Tumors
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
X-Rays
9
Specimen Handling
8
Phantoms, Imaging
8
Magnetic Resonance Spectroscopy
8
Vincristine
5
Nuclear Medicine Department, Hospital
5
Biopsy
5
Doxorubicin
4
Etoposide
3
Dactinomycin
3
Cyclophosphamide
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Temozolomide
2
Radiotherapy, Conformal
2
Radiotherapy
2
Radiation
2
LY3023414
2
Irinotecan
2
talazoparib
1
selinexor
1
pembrolizumab
1
olaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Wilms Tumor
×
entrectinib
×
90 days
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA